Prior to joining SmartPharm as CEO, Dr. Trevejo served as Vice President, Clinical Development at Cyclerion Therapeutics/Ironwood where he helped to advance a diverse clinical pipeline in rare diseases such as sickle cell anemia. Dr. Trevejo joined Ironwood from Visterra, where he was a member of the Executive Team and oversaw the transition to a clinical stage company. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, Dr. Trevejo served as Instructor in Medicine at Harvard Medical School and was Principal Biomedical Scientist at the Draper Laboratory. He began his medical career as a resident at Brigham and Women’s Hospital and then as a Clinical Fellow at Beth Israel Deaconess Medical Center. Dr. Trevejo earned both an MD in Medicine and a PhD in Molecular and Cell Molecular Biology at the Cornell/Rockefeller/Sloan-Kettering MD PhD Program.